In an adult with episodic migraine, should I use Qulipta (atogepant) or Ubrelvy (ubrogepant) for acute migraine treatment?

Qulipta vs Ubrelvy: Wrong Comparison

You're comparing the wrong medications—Qulipta (atogepant) is for migraine prevention, while Ubrelvy (ubrogepant) is for acute migraine treatment. These drugs serve fundamentally different purposes and are not interchangeable 1, 2.

Understanding the Distinction

Ubrelvy (Ubrogepant) - Acute Treatment Only

• FDA-approved exclusively for acute migraine treatment with or without aura 1
• Take it when a migraine attack starts to abort the headache
• Dosed 50-100 mg as needed during attacks
• Achieves pain freedom in 19-21% of patients at 2 hours (vs 12-14% with placebo) 3, 4
• Can be used up to 8 times per 4-week period 5

Qulipta (Atogepant) - Prevention Only

• FDA-approved exclusively for migraine prevention 2
• Take it daily (10-60 mg once daily) to reduce migraine frequency
• Reduces monthly migraine days by 3.7-4.2 days (vs 2.5 days with placebo) 2
• Not indicated for treating active migraine attacks

The Correct Clinical Algorithm

For acute migraine treatment (when you have a migraine):

1. First-line: Start with NSAIDs (ibuprofen, naproxen) or acetaminophen 6
2. Second-line: Add a triptan to NSAID/acetaminophen if inadequate response 6
3. Third-line: Consider Ubrelvy (ubrogepant) or other gepants (rimegepant, zavegepant) only if you fail or cannot tolerate triptan + NSAID combination therapy 6
4. Fourth-line: Lasmiditan if all other treatments fail 6

For migraine prevention (to reduce attack frequency):

• If you have frequent episodic migraines requiring preventive therapy, Qulipta (atogepant) is one option among several preventive medications 2

Can They Be Used Together?

Yes, you can use both simultaneously—atogepant for daily prevention and ubrogepant for breakthrough migraine attacks. This combination is safe and well-tolerated 5, 7. The TANDEM study demonstrated no clinically meaningful drug interactions when using atogepant 60 mg daily with ubrogepant 100 mg as needed for breakthrough attacks 5.

Key Caveats

• Cost matters: Gepants are expensive (annualized cost $4,959-$5,994 for oral formulations) 6. Prioritize less costly options first 6
• Gepants are NOT first-line for acute treatment: The 2025 American College of Physicians guidelines explicitly state that comparative evidence for gepants vs triptan+NSAID combination is uncertain, and gepants may have lower likelihood of pain freedom than combination therapy 6
• Medication overuse headache: Be aware of thresholds—≥10 days/month with triptans, ≥15 days/month with NSAIDs 6
• Drug interactions: Both gepants interact with CYP3A4 inhibitors/inducers 7, 8

Bottom line: These medications don't compete—they complement each other for different indications. Choose Ubrelvy for acute attacks (after trying cheaper options first) and Qulipta for daily prevention if needed.